

AUTHOR INDEX

VOLUME 27

- Aalen, Odd, 107
 Adams, M., 275
 Aiba, Shuichi, 367
 Alexander, W. James, 760
 Allan, J. Davis, 782
 Alpert, Martin L., 422
 Alvarez, Salvador, 646
 Alving, Carl R., 903
 Ambinder, Richard F., 217
 Anderson, R., 257
 Anwar, Hosmin, 220
 Aoki, Fred Y., 753
 Aoyama, M., 595
 Apicella, Michael A., 16
 Arao, Nakako, 565
 Araujo, Fausto G., 491
 Arizpe, H. M., 184
 Arnold, Keith, 192
 Aronoff, George R., 812
 Attfield, P. V., 985
 Ayers, Leona W., 982
 Ayers, Ouida M., 324
 Aznar, Javier, 76
- Bailey, Denis M., 4
 Baird, Anne, 858
 Baker, Carol J., 511
 Baker, Neil R., 468
 Balber, Andrew E., 33
 Baldwin, Jack N., 234
 Bansal, Madhu B., 640
 Barry, Arthur L., 679
 Barry, David W., 167
 Baucks, Regina, 632
 Bawdon, R. E., 436
 Bawdon, Roger E., 874
 Bayoumi, Samir M., 487
 Beale, Angela S., 980
 Beaubien, Arthur R., 720
 Bechard, Douglas L., 263
 Beck, C. F., 879
 Bellora, Mauricio J. Gatto, 137
 Benavente, Maria C., 282
 Benes, Solomon, 724
 Bennett, William M., 897
 Benziger, David P., 769, 774
 Berens, Randolph L., 33
 Bergeron, Michel G., 928
 Berk, Steven L., 646
 Berman, Jonathan D., 916
 Bertram, Miriam A., 515
 Bettex, Jean-David, 350, 353
 Bibler, Mark, 291
 Bies, M., 207
 Bint, Adrian J., 508
 Birk, R. J., 424
 Bistoni, F., 625
 Blaser, Jürg, 343
 Blayo, Marie-Claude, 561
 Blumer, Jeffrey L., 583
 Bode, Robert, 291
 Bodey, Gerald P., 265
 Boeie, Wil A. M., 802
 Bonner, Daniel P., 555
 Boon, R. J., 495
 Boon, Ronald J., 980
 Boozer, Richard M., 42
 Borner, Klaus, 375
 Boscia, Jerome A., 708
 Bowdre, Jean H., 525
- Bowman, Bernard U., Jr., 399, 404, 408
 Box, Quellan T., 181
 Brajtburg, Janina, 172
 Brammer, Keith W., 832
 Brander, Pirkko, 948
 Brandis, Henning, 836
 Brater, D. C., 436
 Brier, Michael E., 812
 Brier, Richard A., 812
 Brion, Nils, 520, 660
 Brochu, Gilles, 928
 Brooks, Dandrea L., 912
 Brown, Michael R. W., 220
 Brummer, Elmer, 363
 Bruns, Wolfgang, 632
 Bryan, Elza R., 102
 Buck, R. E., 207
 Bulkacz, Jaime, 427
 Bullock, Ward E., 291
 Burkley, Linda J., 817
 Burns, Jane L., 46
 Bush, Karen, 555
 Butzler, Jean-Paul, 388
- Caballero, Maria C., 76
 Cafarelli, Robert F., 16
 Canonico, Peter G., 903
 Carbon, Claude, 520, 660
 Carek, Peter J., 817
 Carlson, Karin, 107
 Carter, Walker T., 876
 Carter, W. T., 674
 Casal, Manuel J., 282
 Cauchy, Michael J., 720
 Chaffin, Donald, 531
 Chamberlain, Paul D., 858
 Chambers, Henry F., 685
 Chan, Ying-Pui M., 192
 Chau, P. Y., 872
 Cheng, Yuan Rong, 828
 Cheng, Yung-Chi, 416, 445
 Cheriyan, U. O., 184
 Chiou, Jwo-Farn, 416
 Chisholm, D. R., 207
 Chonmaitree, Tasnee, 181
 Chow, Anthony W., 749
 Christenson, Bernard, 570
 Citron, Diane M., 162, 657
 Clavier, Françoise, 561
 Cohenford, Menashi, 479, 715
 Coignau, Hugo, 388
 Colby, Steven D., 71
 Congeni, Blaise L., 181
 Contrepoint, Alain, 520, 660
 Cook, James L., 11
 Cooksey, Robert C., 234
 Coombes, James D., 535
 Corey, Lawrence, 203
 Cornett, James B., 4
 Costerton, J. W., 619
 Couch, Robert B., 309
 Couetdic, Gerard, 280
 Cramer, William A., 836
 Craven, Philip C., 868
 Crawmer, Bruce P., 769
 Creger, Richard J., 413
 Crider, Steven R., 71
 Critchlow, Cathy, 203
 Crooke, Stanley T., 460
- Dale, Jeremy W., 989
 Dandu, Vijay R., 977
 D'Aquino, Miguel, 137
 Datema, Roelf, 753
 David, Hugo L., 701
 Debbia, Eugenio, 615
 De Grandis, Stephanie A., 938
 DeHertogh, Deborah A., 670
 Delaha, Edward C., 485
 Delatour, Frédérique, 520
 Del Bene, Victor E., 817
 DeLong, Donald C., 102
 de Lorenzo, Victor, 666
 de Miguel, Constantino, 76
 De Mol, Patrick, 388
 Desaulniers, Denis, 928
 Desjardins-Giasson, Suzanne, 720
 Desjardins, Robert E., 525
 Després, Jean-Paul, 928
 Deybach, Jean-Charles, 520
 Dhruv, R., 263
 Diana, G. D., 883
 Dias, M. Beatriz Souza, 968
 Dickinson, Cathy S., 332
 Didolkar, Mukund S., 977
 DiPiro, Joseph T., 487
 DiVincenzo, Cathy A., 712
 Divo, Alan A., 21
 Dobson, Richard A., 4
 Donowitz, Gerald R., 125
 Douce, Richard, 291
 Douglas, John M., 203
 Dowling, John N., 272
 Drake, Thomas A., 320
 Dromer, Françoise, 660
 Drupa, Ilga, 11
 Drusano, G. L., 605
 Duff, Ronald G., 197
 Duke, Arit E., 277
 Dupont, Marie-Jeanne, 280
 Dure, Leon, 309
 Dzink, JoAnn L., 663
- Edwards, Morven S., 511
 Elberg, Svetlana, 172
 Eliopoulos, George M., 357, 782
 Eliopoulos, G. M., 28
 Ellis, M. Nixon, 167
 Ellner, Jerrold J., 413
 Emmerman, J., 424
 English, Jan, 897
 Eng, Robert H. K., 688
 Ericson, Ann-Christin, 753
 Exelby, Alice, 102
- Fairgrieve, John S., 197
 Fancher, M. J., 883
 Fanucchi, Michael P., 733
 Faurisson, François, 520
 Feinberg, Aaron, 733
 Fenwick, Raymond G., 460
 Ferraro, Mary Jane, 782
 Finegold, S. M., 674
 Finegold, Sydney M., 876
 Fiore, Dario, 977
 Fisher, Melanie A., 745
 Fish, R. G., 275
 Fish, Wallace R., 33
 Flepp, Markus, 350, 353
- Fliegelman, Robert M., 429
 Fontana, Roberta, 828
 Forrest, A., 605
 Fowlston, S., 966
 Fox, Jack J., 733
 Fox, M. P., 883
 Frank, Karl B., 445
 Freij, Bishara J., 431
 Friedhoff, Lawrence T., 263
 Friedman-Kien, Alvin E., 763
 Fuchs, Peter C., 679
 Fujii, Tadashi, 608, 612
 Fujiwara, Tatsushi, 65
- Galask, Rudi, 337
 Gallion, Corinne, 704
 Garaci, E., 625
 Garagusi, Vincent F., 485
 Garaud, Jean-Jacques, 520
 Garcia-Bustos, Jose F., 791
 Garcia-Prats, Joseph A., 511
 Garcia-Riestra, Carlos, 114
 Gauntt, C. J., 184
 Gavan, Thomas L., 982
 Geary, Timothy G., 21
 Gebhart, Connie J., 55
 Gentry, Layne O., 683
 George, W. Lance, 643, 966
 Gerlach, E. Hugh, 413, 982
 Gerson, Benjamin, 357
 Ghysels, Guido, 388
 Gibson, Gene A., 745
 Gilbert, Brian E., 309
 Gilbert, David N., 897
 Giles, Penelope, 953
 Gillespie, Matthew T., 79
 Ginsberg, Bernard P., 422
 Giovenella, Albert J., 961
 Goering, Richard V., 455
 Gokhale, Rajeev, 487
 Goldstein, Ellie J. C., 162, 422, 657
 Goodman, Larry J., 429
 Goossens, Herman, 388
 Gootz, Thomas D., 739
 Gorbach, Sherwood L., 968
 Gorbea, Héctor F., 570
 Gordin, Fred M., 452, 648
 Gordon, Kathryn P., 37
 Gordon, Kathy P., 739
 Gottlieb, Alan, 270
 Grados, Oscar, 388
 Grappell, Sarah F., 961
 Greenberg, Stephen B., 953
 Greenmill, David H., 868
 Griffin, Karen E., 495
 Grimont, Patrick A. D., 806
 Grossgarten, Michaela, 836
 Gruber, William C., 511
 Guaderas, Juan, 646
 Guibert, Jacqueline, 177
 Gurney, Michael, 652
 Gurusiddaiah, S., 239
- Hackbarth, Corinne J., 135, 224, 320, 340, 452, 685
 Hadley, W. Keith, 958
 Hamilton, Bruce, 291
 Hancock, Counce, 733
 Hand, W. Lee, 42

- Hanson, Brian D., 916
 Hara, Tetsuro, 589
 Harman, Colleen P., 125
 Harmsen, Theo, 802
 Harris, Betty, 876
 Harris, B. H., 674
 Harris, Deborah, 953
 Hatin, Isabelle, 561
 Hawkins, Stephen S., 263
 Hayes, Nancy, 309
 Hedges, Robert W., 479
 Heifets, Leonid B., 11
 Herrin, Thomas R., 197
 Higgins, Peter G., 846
 Hill, Gale B., 324
 Hoagland, Vicki L., 297
 Ho, Dah Hsi, 265
 Höffken, Gert, 375
 Holland, Susan, 989
 Holmes, King K., 203
 Holtsclaw-Berk, Shirley, 646
 Hori, Seiji, 650
 Hornstein, Michele J., 806
 Houang, Elizabeth T., 964
 Houghton, Donald C., 897
 Huang, Cheng-Hsiung, 460

 Iida, Kyoko, 93
 Ikeuchi, Toru, 473
 Imada, Akira, 821
 Imanaka, Tadayuki, 367
 Ings, Robert M. J., 535
 Innocent, Habyaremye, 388
 Inoue, Matsuhisa, 608, 612
 Inouye, Shigeharu, 589
 Iravani, Abdollah, 158, 449
 Iseman, Michael D., 11
 Ishitsuka, H., 595
 Isono, Kiyoshi, 230
 Iwanaga, Tomoaki, 93

 Jackson, Andre J., 977
 Jacobus, Nilda V., 968
 Jacoby, George A., 479, 715
 Janicke, David M., 16
 Jantzen, Jan-Peter, 874
 Jehl, François, 503
 Jensen, James B., 21
 Johansson, Nils-Gunnar, 753
 Johnson, Curtis A., 578
 Johnson, J., 468
 Johnson, Judith A., 774
 Johnson, Kenneth, 874
 Johnson, Paulette, 314
 Jokipii, Anssi M. M., 948
 Jokipii, Liisa, 948
 Jones, J., 966
 Jones, Mary, 646
 Jones, Ronald N., 413, 679, 982
 Jonsson, Monica, 128
 Joos, Benda, 350, 353
 Joshi, J., 605
 Jouvenot, Michelle, 280
 Jupeau, Annie M., 806
 Jusko, William J., 16

 Kadurugamuwa, Jagath L., 220
 Kany, Robert J., Jr., 1
 Kaplan, Raymond L., 429
 Karney, Walter W., 652
 Kasbekar, Durgadas P., 974
 Kato, H., 132
 Katz, Eugene, 974
 Kaye, Donald, 708
 Kazuno, Yuzo, 589

 Kelley, Eileen, 600
 Kelly, Jesse P., 760
 Kende, Meir, 903
 Keppeler, Hans, 632
 Kessler, R. E., 207
 King, Charles H., 413
 King-Thompson, Neva L., 42
 Klein, Claire, 660
 Klein, Richard J., 763
 Knight, Susan S., 277
 Knight, Vernon, 60, 309
 Knowlton, Douglas R., 306
 Kobasa, William D., 708
 Kobayashi, George S., 172
 Kobayashi, G. S., 302
 Kobayashi, Seiki, 65
 Koeppe, Peter, 375
 Kohlhepp, Sue, 897
 Kohnen, Paul W., 897
 Kondo, Masahiro, 821
 Konno, Masatoshi, 851
 Kraaijeveld, Cornelis A., 802
 Krieger, John N., 332
 Kuhr, M. F., 883
 Kung, J. T., 184
 Kuno, Mitsuzo, 821
 Kurioka, Susumu, 650
 Kurtz, Harold J., 55
 Kwok, Y.-Y., 427

 LaFon, Stephen W., 33
 Laishley, Edward J., 863
 Larsson, Alf, 753
 Lawrence, Adam G., 964
 Leathers, Timothy, 892
 LeBlanc, Barbara, 265
 LeBlanc, Donald J., 439
 LeBras, Jacques, 561
 Lecaillon, Jean-B., 177
 Ledergerber, Bruno, 350, 353
 Lee, Ken, 652
 Lee, Linda N., 439
 Lefler, Eli, 363
 Leitner, F., 207
 Lemieux, Michel, 928
 Lerner, Stephen A., 114, 670
 Leslie, J., 605
 Lessard, Céline, 928
 Leung, Y. K., 872
 Levy, Jack, 46, 388
 Levy, Jean-Claude, 520
 Leyland-Jones, Brian, 733
 Lietman, Paul S., 217
 Lindholm-Levy, Pamela J., 11
 Lindqvist, Lennart, 943
 Lin, Jung-Chung, 971
 Little, J. R., 302
 Livermore, D. M., 872
 Lockerby, Deirdre L., 863
 Lode, Hartmut, 375
 Longfield, Jenice N., 652
 Looker, Douglas L., 33
 López-Nieto, Manuel J., 380
 Louv, William C., 760
 Lozano, Maria C., 76
 Lu, Y.-S., 436
 Luft, Friedrich C., 812
 Luman, J. Ilice, 912
 Lüthy, Ruedi, 350, 353
 Lyon, Bruce R., 79

 MacCulloch, Donald, 672
 Macdonald, Cameron M., 535
 MacGregor, Rob Roy, 745
 Madigan, Sanford, 974

 Mäkinen, Kauko K., 96
 Maniatis, Antony, 515
 Mao, James C.-H., 197
 Marconi, P., 625
 Marion, Patricia L., 277
 Markowitz, Sheldon M., 419
 Marks, Melvin I., 908
 Marriott, Michael S., 832
 Marr, J. Joseph, 33
 Marshall, Rosemarie, 640
 Martin, Jerry R., 314
 Martin, Juan F., 380
 Martin, R. Russell, 953
 Masters, P. J., 495
 Matsuda, Makoto, 650
 Matsushashi, Yuji, 589
 Matthews, Thomas R., 277
 Mayer, Philip R., 812
 May, John W., 79
 Mayor, Gilbert, 897
 Mazzolla, R., 625
 McCabe, Robert E., 491
 McColm, Andrew A., 925
 McCormack, William M., 724
 McCoy, Leslie F., 769
 McCracken, George H., Jr., 141, 431, 655
 McDevitt, David A., 272
 McKinlay, M. A., 883
 McLarty, Jerry W., 912
 Medeiros, Antone A., 479, 715
 Medoff, G., 302
 Medoff, Gerald, 172
 Mellits, E. David, 217
 Mendelman, Paul M., 46
 Mendez, Enrique, 791
 Menzies, Rosalie E., 672
 Merola, A. John, 399, 404, 408
 Métras, Jacques, 928
 Michel-Briand, Yvon, 280
 Milhous, Wilbur K., 525
 Miller, F. DeWolfe, 102
 Miller, Mahlon F., 314
 Mills, John, 270, 648
 Mintz, Paul D., 125
 Mirabelli, Christopher K., 460
 Misiek, M., 207
 Mitsuhashi, Susumu, 473, 608, 612
 Mizuguchi, Yasuo, 541
 Modai, Jacques, 177
 Moellering, R. C., Jr., 28
 Moellering, Robert C., Jr., 357, 782
 Monteil, Henri, 503
 Monto, Arnold S., 102
 Moore, Richard D., 217
 Mordenti, Joyce, 887
 Murakami, Kazuhisa, 727
 Myers, Carolyn M., 583

 Nacucchio, Marcelo C., 137
 Nagata, Akihisa, 921
 Nakanishi, Hiroshi, 93
 Nam, Doo H., 798
 Natelson, Ethan A., 683
 Needham, Cynthia A., 499
 Nelson, Donald J., 33
 Nesbit, Robert R., 487
 Nevárez, Minerva, 246
 Newton, Bruce R., 449
 Ng, Wilson W. S., 872
 Nickel, J. C., 619
 Nikaido, Hiroshi, 84, 393
 Ninomiya, Y., 595

 Nisbet, Louis J., 961
 Nohara, Chieko, 565
 Nolan, Charles, 37
 Nombela, César, 120
 Nord, Carl Erik, 943
 Norrby, S. Ragnar, 128
 Nozawa, R. T., 132
 Nugent, K. M., 692
 Nunn, Barbara, 858

 Öberg, Bo, 753
 O'Brien, Cheryl A., 583
 Ogawa, Hidemasa, 473
 Ogawa, Midori, 541
 Ohlgive, K. K., 184
 Ohm-Smith, Marilyn J., 958
 Ohnuki, Tetsuo, 367
 Okamoto, Ryoichi, 612
 Okonogi, Kenji, 821
 Olsen, Kurt D., 431, 655
 Ono, Yasuko, 921
 Ophelm, Kent E., 531
 Osada, Hiroyuki, 230
 Osada, Yasuaki, 473
 Otani, Tsuyoshi, 473
 Otis, Ellen R., 197
 Ottolenghi, Abramo C., 399, 404, 408
 Otto, M. J., 883

 Pagano, Joseph S., 971
 Palomares, Jose C., 76
 Parker, Steven W., 16
 Pasculle, A. William, 272
 Pedler, Stephen J., 508
 Perea, Evelio J., 76
 Perlin, Michael H., 114
 Perlman, Alan M., 363
 Petrak, Russell M., 429
 Petzold, C. Rosemarie, 337
 Pezzi, Nieves, 791
 Philippon, Alain M., 806
 Philips, Frederick S., 733
 Phillips, Robert J., 846
 Pihl, Evelyn, 337
 Pijck, Jacques, 574
 Pinney, R. J., 985
 Pintado, Concepción, 120
 Plorde, James J., 37
 Plorde, J. J., 739
 Prabhala, Rao H., 640
 Price, K. E., 207
 Prinzing, Claus, 375
 Puccetti, P., 625
 Pugsley, Anthony P., 666
 Pursiano, T. A., 207

 Quarles, John M., 309

 Rabin, Harvey R., 863
 Rakusan, Tamara A., 181
 Ramírez-Ronda, Carlos H., 246, 570
 Ramos, Filomena R., 380
 Randall, Eileen, 424
 Rao, Bhavani, 640
 Rastogi, Nalin, 701
 Rayburn, William, 337
 Raymond, Gilles, 928
 Reed, Michael D., 583
 Reeves, William C., 203
 Reinhardt, John F., 643, 966
 Rein, Michael F., 332
 Reiszner, E., 28
 Remington, Jack S., 491

- Remington, Michael L., 203
 Rench, Marcia A., 511
 Reynolds, Rolfe B., 760
 Richard, George A., 158, 449
 Richardson, Kenneth, 832
 Rill, Wayne L., 903
 Rissing, J. Peter, 487
 Robinson, William S., 277
 Rodriguez, Fernando C., 282
 Rodríguez, Julie R., 246, 570
 Rogge, Mark C., 578
 Rollins, Larry D., 439
 Roselle, Gary A., 291
 Rosenstock, Joel, 652
 Rossi, Lucia, 828
 Rotgef, Rafael, 120
 Rouan, Marie-C., 177
 Ruhr, Elke, 841
 Ruseska, I., 619
 Rusnak, Michael G., 340
 Ruxer, R., 605
 Ryan, D. Michael, 925
 Ryder, Neil S., 252
 Ryu, Dewey D. Y., 798
- Sabbaj, Jacobo, 297
 Sahl, Hans-G., 836, 841
 Sakata, Yasutaka, 141, 655
 Salvador, Concepción, 120
 Sande, Merle A., 135, 224, 320, 340, 452, 685
 Sander, Donna S., 306
 Sanders, Christine C., 455
 Sanders, W. Eugene, Jr., 455
 San Joaquin, Venusto H., 908
 Sato, Kenichi, 473, 608, 612
 Sato, Masamichi, 473
 Scavizzi, Maurice R., 806
 Schimpff, S., 605
 Schito, Gian Carlo, 615
 Schlessinger, David, 172
 Schmidt, L. H., 146, 151
 Schoeller, Jean-P., 177
 Schwartz, Daniel R., 172
 Scott, Kenyon G., 340, 452, 685
 Segreti, John, 429
 Shafran, Stephen D., 749
 Shalit, Itamar, 908
 Shelley, M. D., 275
 Shih, W. J., 297
 Shimada, Jingoro, 650
 Shipkowitz, Nathan L., 197
 Shoeb, Hussein A., 399, 404, 408
 Siegenthaler, Walter, 353
- Sievers, Gunnel, 96
 Singh, S. K., 239
 Sköld, Ola, 933
 Skurray, Ronald A., 79
 Slocombe, B., 495
 Smee, Donald F., 277
 Smith, Arnold L., 46, 531
 Smith, Craig R., 217
 Smith, L. Patrick, 652
 Smith, M. Carolyn, 971
 Smith, Sharon M., 688
 Snippe, Harm, 802
 Socransky, Sigmund S., 663
 Sommers, Herbert M., 982
 Sordelli, Daniel O., 137
 Spector, Stephen A., 600
 Speelman, Peter, 227
 Srivastava, Sujana, 102
 Stagno, Sergio, 760
 Stamm, Walter E., 203
 Standiford, H., 605
 Staneck, Joseph L., 291
 Stapleton, M. J., 468
 Steele, Lorraine C., 912
 Steen, Rolf, 933
 Stern, Robert C., 583
 Stevens, David A., 363
 Stevenson, Roselynn M. W., 938
 Stone, Benjamin B., 343
 Stull, Terrence L., 46
 Sugi, H., 132
 Suhara, Y., 595
 Sullam, Paul M., 135, 224, 320, 685
 Sullivan, Robert, 291
 Sun, Chong-Son, 60
 Sun, Ming, 192
 Susaki, Kiyoshi, 565
 Sutherland, R., 495
 Sutter, Vera L., 424, 427
 Suzuki, Yasuhiko, 921
 Swartz, Glenn M., Jr., 903
 Sweeney, Kristin G., 499
 Sweet, Richard L., 958
 Sykes, Richard B., 555
 Sypherd, Paul S., 892
- Tachibana, Akio, 565
 Takeuchi, Tsutomu, 65
 Tally, Francis P., 968
 Tanabe, Masanobu, 65
 Tanaka, S. Ken, 555
 Täuber, Martin G., 135, 224, 320, 340, 685
- Tauber, William B., 652
 Tennent, Jan M., 79
 Tenover, Fred C., 37, 739
 Tenovuo, Jorma, 96
 Thadepalli, Haragopal, 640
 Thauvin, Claudie, 357
 Thierry, Robert C., 503
 Thomas, Debra, 125
 Thornsberry, Clyde, 679
 Threlkeld, Norma, 431
 Toda, Masato, 565
 Tomasz, Alexander, 695
 Tonin, Enrico, 828
 Traub, B., 879
 Trenholme, Gordon M., 429
 Troke, Peter F., 832
 Tsai, Y. H., 207
 Tsuji, Akioyoshi, 515
 Tunér, Kajsa, 943
 Turcan, Robert G., 535
 Twitty, James A., 817
 Tyrrell, David A. J., 846
- Ubukata, Kimiko, 851
 Udou, Takezo, 541
 Umeda, I., 595
 Une, Tsutomu, 473
- Vaara, Martti, 548
 Vallner, Joseph J., 487
 van Tiel, Frank H., 802
 Varaldo, Pietro Emanuele, 615
 Varner, Michael, 337
 Vecchiarelli, A., 625
 Venezio, Frank R., 712
 Verdier, Françoise, 561
 Verghese, Abraham, 499
 Vertut-Croquin, Aline, 172
 Vidal, Pedro M., 733
 Viljanen, Petri, 548
 Visscher, David, 812
 von Esch, Anne M., 197
 Vontver, Louis A., 203
 Vorland, Lars H., 107
 Vu, Hanh, 393
 Vuye, Armand, 574
- Waddell, David, 916
 Wade, J., 605
 Wagner, Roland B., 4
 Wallace, Richard J., Jr., 912, 953
 Ward, Gilbert E., 55
 Ward, Richard L., 306
 Warren, Richard L., 468
- Watanabe, Kyoichi A., 733
 Weatherly, Norman F., 525
 Weber, Allan, 531
 Weinberg, Winkler G., 652
 Weisholtz, Steven, 695
 Welch, David F., 908
 Welch, William D., 874
 Welling, Peter G., 578
 Welty, Gina S., 449
 Wentland, Mark P., 4
 Werner, Georges H., 846
 Werner, Vicki, 455
 Wexler, H., 674
 Wexler, Hannah M., 876
 Whalen, J. W., 239
 White, A. R., 495
 Widger, William R., 836
 Williams, Denise S., 419
 Williams, Linda, 733
 Williams, Michael E., 125
 Williams, Sue, 37
 Willis, Greg, 309
 Willmann, John S., 846
 Wilson, Rebecca W., 912
 Wilson, Samuel Z., 60, 309
 Wofsy, Constance B., 648
 Wong, Justina, 749
 Wood, Bruce A., 683
 Wood, N. C., 592
 Wyde, Philip R., 60
- Yamada, Hozumi, 93
 Yamada, Takeshi, 921
 Yamaguchi, Masaya, 93
 Yamanouchi, Takahisa, 921
 Yamashita, Naoko, 851
 Yamashita, Toyoko S., 583
 Yisak, Wolde-Ab, 753
 Yokota, T., 132
 Yoshida, Tadashi, 589, 727
 Yoshimura, Fuminobu, 84
 Young, Charles W., 733
 Young, Lowell S., 515
 Young, Stephen A., 739
 Yukishige, Koichi, 821
- Zabransky, R. J., 424
 Zajac, Barbara A., 745
 Zak, Oto, 220
 Zar, Fred A., 1
 Zerial, Aurelio, 846
 Zhou, Hong-Hao, 192
 Zimmerman, Stephen W., 578
 Zinner, Stephen H., 343

SUBJECT INDEX VOLUME 27

- A21978C₁
in vitro activity, 357
mechanism of action, 357
- AC 1370
see cefpimizole
- 2-Acetylpyridine thiosemicarbazones
N. gonorrhoeae, 570
- Acyclovir
combined with vidarabine, 600
cytomegalovirus, 600
experimental infections
herpes simplex virus, 167
- Adenylyl dihydrostreptomycin
accumulation in *E. coli*, 114
- Aeromonas hydrophila*
β-lactamases
AER-1, 479
carbenicillin-hydrolyzing, 479
- Aeromonas* spp.
ciprofloxacin, 643
enoxacin, 643
norfloxacin, 643
tetracycline, 643
trimethoprim-sulfamethoxazole, 643
- African trypanosomes
inosine analogs, 33
- Alafosfalin
anaerobic bacteria, 961
- Alcaligenes faecalis*
β-lactamase, 608
- Alveolar macrophages
antibiotic uptake, 42
smokers, 42
- AMA-1080
see carumonam
- Amifloxacin
antibacterial activity, 4
comparative activity, 449
disposition in laboratory animals, 774
E. coli, 449
high-pressure liquid chromatography, 769
in vitro activity
culture medium, 449
inoculum size, 449
pH changes, 449
metabolism, 774
pharmacokinetics, 769
S. saprophyticus, 449
urinary tract infections, 449
- Amikacin
concentrations in body fluids
pentobarbital, 720
renal disposition, 520
8-(L-Aminoadipyl)-L-cysteinyl-D-valine
conversion to isopenicillin N, 380
- γ-Aminobutyric acid
cephalosporins, 650
rat synaptic membranes, 650
- Aminoglycosides
2"-O-nucleotidyltransferase
enzymatic modification, 670
resistance, 670
3-phosphotransferase
DNA probes, 739
structural genes, 739
polymorphonuclear leukocytes, 712
pseudodisaccharide
dactimicin, 589
renal disposition, 520
- 5-Aminoimidazole-4-carboxamide
high-pressure liquid chromatography, 977
- Amoxicillin
-clavulanic acid
bacteriuria, 508
B. catarrhalis, 912
H. influenzae, 912
lower respiratory tract infections, 912
- Amphotericin B
comparative activity, 302, 363
erythrocyte lysis, 172
experimental infections
blastomycosis, 363
C. albicans, 625
immunoadjuvant activity, 625
methyl ester
comparative activity, 302
N-D-ornithyl, 302
oxidative damage, 172
rapid infusion
ventricular fibrillation, 868
- Ampicillin
Campylobacter spp., 429
combined with sulbactam
anaerobic bacteria, 876
comparative activity, 429
- Anaerobic bacteria
alafosfalin, 961
ampicillin
cefbuterazone, 162, 640, 674, 749
ciprofloxacin, 427
female genital tract infections
antimicrobial susceptibilities, 324
HR 810, 413
moxalactam MICs, 424
quinolones, 657
Sch 34343, 749
sulbactam
- Antiglobulin tests
clavulanic acid, 125
- Antimalarial drugs
antifol
in vitro activity, 525
mechanism of resistance, 525
P. falciparum, 21
- Antimycotic agents
SF 86-327, 252
- Antiviral agents
enzyme immunoassay, 802
MICs, 802
- Apalcillin
comparative activity, 782
platelet function, 683
- Aphidicolin
herpesvirus DNA polymerase, 445
- Arabinosyladenine monophosphate
ground squirrel hepatitis virus, 277
virion-associated DNA polymerase re-
duction, 277
- Ascamycin
mechanism of action, 230
selective toxicity, 230
- 2-Azahypoxanthine
high-pressure liquid chromatography, 977
- Aztreonam
combinations
clindamycin, 246
respiratory tract infections, 246
comparative activity, 1, 388, 872
endocarditis, 1
- enteropathogens, 388
experimental infections
E. coli K1, 655
H. influenzae type b, 655
meningitis, 655
gonorrhea, 265
P. aeruginosa, 1, 872
penetration into bronchial secretions, 263
pharmacokinetics, 16
- BA-41,799
experimental infections
malaria, 146
P. cynomolgi, 146
- Bacillus cereus*
lactoperoxidase, 96
myeloperoxidase, 96
- Bacillus circulans*
butirosin
biosynthesis, 798
sporulation, 798
- Bacteriodes* spp.
cefbuterazone, 968
- Bacteriuria
amoxicillin-clavulanic acid, 508
pregnancy, 508
- Bay I 9139
comparative activity, 363
experimental infections
blastomycosis, 363
- Bay n 7133
comparative activity, 363
experimental infections
blastomycosis, 363
- BCG vaccine
herpes simplex virus infections, 203
- Bioassay
ciprofloxacin, 353
comparative studies, 353
- BIOLF-70
antimycarditic activity, 184
experimental infections
coxsackievirus, 184
- Bismuth salts
echovirus, 306
poliovirus, 306
reovirus, 306
rotavirus, 306
- Bis-triazole
derivatives
UK-49,858, 832
- Bithionol
G. lamblia, 65
T. vaginalis, 65
- Blastomycosis
experimental
amphotericin B, 363
Bay I 9139, 363
Bay n 7133, 363
ICI 153066, 363
ketoconazole, 363
- Bleomycin
E. coli DNA breakage, 460
plasmid R6K elimination, 985
- BMV-25182
see cefbuterazone
- BMV-28142
comparative activity, 207, 515
experimental infections

- meningitis, 340
in vitro activity, 265, 574, 679
- Branhamella catarrhalis*
amoxicillin-clavulanic acid, 912
antibiotic susceptibility, 499
comparison with colonizing isolates, 499
 β -lactamase-positive, 912
 β -lactamase production, 646
lower respiratory tract infections, 912
pneumonia, 499
R plasmid, 120
susceptibility, 646
- Butirosin
biosynthesis, 798
sporulation, 798
- Campylobacter coli*
resistance factors, 37
R plasmids, 37
- Campylobacter jejuni*
resistance factors, 37
R plasmids, 37
- Campylobacter* spp.
ampicillin, 429
antimicrobial agent activity, 55
cefotaxime, 429
cephalothin, 429
chloramphenicol, 429
ciprofloxacin, 429
clindamycin, 429
doxycycline, 429
erythromycin, 429
gentamicin, 429
nalidixic acid, 429
pigs, 55
sulbactam, 429
trimethoprim-sulfamethoxazole, 429
- Cancer patients
ceftazidime pharmacokinetics, 605
- Candida albicans*
experimental infections
amphotericin B, 625
UK-49,858, 832
- Candida* spp.
chlorpromazine, 692
- Carbenicillin
hydrolysis by β -lactamase
A. hydrophila AER-1, 479
- Carumonam
antibacterial activity, 821
- Cefamandole
cardiac surgery, 928
concentration in atrial appendages, 928
- Cefazolin
prophylaxis
cesarean section, 337
- Cefbuperazone
anaerobic bacteria, 162, 640, 674, 749, 817
Bacteriodes spp., 968
comparative activity, 162, 817
female genital tract isolates, 958
 β -lactamase contribution to resistance, 817
- Cefmetazole
M. chelonae, 282
M. fortuitum, 282
- Cefoperazone
experimental infections
comparative activity, 708
E. aerogenes, 708
endocarditis, 708
- M. avium-intracellulare*, 132
pleural fluid
clearance, 93
penetration, 93
- Ceforanide
M. tuberculosis, 11
pharmacokinetics, 487
protein binding, 487
- Cefotaxime
Campylobacter spp., 429
comparative activity, 429
experimental infections
meningitis, 340
valvular lesions, 320
M. avium-intracellulare, 132
resistance test, 672
- Cefotiam
pharmacokinetics, 177
- Cefpimizole
clinical isolates, 982
comparative activity, 982
experimental infections
meningitis, 340
- Cefpiramide
comparative activity, 782
- Cefsulodin
comparative activity, 1
endocarditis, 1
P. aeruginosa, 1
renal interaction, 660
urinary pH, 660
- Ceftazidime
cancer patients, 605
cardiac vegetations, 925
combinations
piperacillin, 605
tobramycin, 605
fibrin clots, 925
pharmacokinetics, 605, 925
- Ceftizoxime
M. avium-intracellulare, 132
- Ceftriaxone
pediatric infections, 181
pharmacokinetics, 192
skin infections, 648
soft tissue infections, 648
urinary tract infections, 158
- Cephalosporins
C. freundii, 727
moxalactam binding, 727
- Cephalosporins
 γ -aminobutyric acid inhibition, 650
BMJ-28142, 679
broad-spectrum
BMJ-28142, 265
DN-9550, 473
half-lives, 887
HR 810, 388
M. tuberculosis, 11
rat synaptic membranes, 650
subinhibitory concentrations
K. pneumoniae, 220
- Cephalothin
Campylobacter spp., 429
comparative activity, 429
- Cepharmycins
cefbuterazone, 640
- Cephems
M. avium-intracellulare susceptibility, 132
- Cesarean section
prophylaxis
cefazolin, 337
- moxalactam, 337
- Chlamydia trachomatis*
growth inhibition, 953
HeLa cells, 953
human prostate cells, 953
McCoy cells, 953
nonoxynol-9, 720, 760
zinc, 953
- Chloramphenicol
Campylobacter spp., 429
comparative activity, 429
H. influenzae, 46
resistance
permeability barrier, 46
- Chloroquine
erythrocytes
uptake, 561
P. falciparum, 561
- Chlorpromazine
Candida spp., 692
- Cilastatin
combined with imipenem
pharmacokinetics, 511
cystic fibrosis patients, 583
imipenem-
high-dose treatment, 745
pharmacokinetics, 431
pharmacokinetics, 583
- Ciprofloxacin
absorption, 350
Aeromonas spp., 643
anaerobic bacteria, 427
bioassay, 353
Campylobacter spp., 429
comparative activity, 388, 427, 429
enteropathogens, 388
experimental infections
P. aeruginosa, 452
pneumonia, 452
high-pressure liquid chromatography, 353, 531
pharmacokinetics, 350, 375
P. shigelloides, 643
S. aureus, 688
- Citrobacter freundii*
cephalosporinase, 727
moxalactam, 727
- Clavulanic acid
amoxicillin-
B. catarrhalis, 912
H. influenzae, 912
lower respiratory tract infections, 912
antiglobulin tests, 125
combined with amoxicillin
bacteriuria, 508
efficacy, 291
safety, 291
- Clindamycin
Campylobacter spp., 429
combinations
aerobic gram-negative bacilli, 246
aztreonam, 246
respiratory tract infections, 246
tobramycin, 246
comparative activity, 429
- Clofazimine
prostaglandins, 257
- Clostridium difficile*
L-cysteine, 419
penicillin, 419
- Clostridium pasteurianum*
metronidazole reduction, 863
phosphoroclastic reaction, 863

- Cloxacillin
cardiac surgery, 928
concentration in atrial appendages, 928
- Colistin
M. aurum, 701
- Colitis
experimental
temocillin, 980
- Continuous ambulatory peritoneal dialysis
vancomycin pharmacokinetics, 578
- Coxsackievirus
experimental infections
BIOLF-70, 184
- Cyclic lipopeptide antibiotics
A21978C₁, 357
- L-Cysteine
C. difficile, 419
penicillin, 419
- Cystic fibrosis
cilastatin, 583
imipenem, 583
- Cytomegalovirus
acyclovir, 600
vidarabine, 600
- Dacarbazine
degradation product
2-azahypoxanthine, 977
high-pressure liquid chromatography, 977
metabolite
5-aminoimidazole-4-carboxamide, 977
- Dactimicin
comparative activity, 589
- Dapsone
prostaglandins, 257
- [2-¹¹C]-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodocytosine
biotransformation, 733
elimination, 733
herpesvirus infections, 733
immunosuppressed patients, 733
- Dibekacin
renal disposition, 520
cis-Dichlorodiammineplatinum (II)
biliary excretion, 275
- 4,6-Dichloroflavin
comparative activity, 595
mechanism of action, 595
- Dichlorophene
G. lumbria, 65
T. vaginalis, 65
- Dictyostelium discoideum*
nystatin resistance, 974
- 9-(3,4-Dihydroxybutyl)guanine
enantiomers
antiherpesvirus effects, 753
pharmacokinetics, 753
- 9-(1,3-Dihydroxy-2-propoxymethyl)-guanine
ground squirrel hepatitis virus, 277
herpes simplex virus
infections in mice, 763
latency, 763
virion-associated DNA polymerase reduction, 277
- DN-9550
in vitro activity, 473
- DNA polymerase
Epstein-Barr virus, 416
herpesvirus
aphidicolin, 445
phosphonoformate, 445
nucleoside analogs, 416, 445
- DNA probes
aminoglycoside 3-phosphotransferase structural genes, 739
- Doxycycline
Campylobacter spp., 429
comparative activity, 429
- Echovirus
bismuth salts, 306
- Edwardsiella tarda*
comparative activity of selected antimicrobial agents, 966
- Endocarditis
experimental
cefoperazone, 708
E. aerogenes, 708
enoxacin, 708
gentamicin, 224
pefloxacin, 685
S. aureus, 685
teicoplanin, 135
- Enoxacin
Aeromonas spp., 643
experimental infections
comparative activity, 708
E. aerogenes, 708
endocarditis, 708
P. shigelloides, 643
- Enteric viruses
bismuth salts, 306
- Enterobacter aerogenes*
experimental infections
cefoperazone, 708
endocarditis, 708
enoxacin, 708
- Enterobacter cloacae*
β-lactamases, 393, 455
β-lactams
hydrolysis, 393
penetration, 555
resistance, 455
mechanism of resistance, 393
outer membrane proteins, 455
- Enterococci
Sch 34343, 28
trimethoprim
alone, 71
with sulfamethoxazole, 71
- Enteropathogens
aztreonam, 388
ciprofloxacin, 388
HR 810, 388
norfloxacin, 388
ofloxacin, 388
RU28965, 388
- Enviroxime
comparative activity, 595
mechanism of action, 595
rhinovirus infections, 102
- Enzyme immunoassays
antiviral agents, 802
monoclonal antibodies, 802
- Epstein-Barr virus
DNA polymerase, 416
nucleoside analogs, 416, 971
- Erythrocytes
amphotericin B, 172
chloroquine uptake, 561
lysis, 172
oxidative damage, 172
- Erythromycin
Campylobacter spp., 429
comparative activity, 429
resistance
L. micdadei, 272
L. pneumophila, 272
streptococci
resistance determinant, 439
tissue culture cells
accumulation, 314
egress, 314
uptake, 314
- Escherichia coli*
adenylyl dihydrostreptomycin accumulation, 114
amifloxacin, 449
bleomycin, 460
cytoplasmic membrane, 666
DNA breakage, 460
experimental infections
aztreonam, 655
meningitis, 655
β-lactam diffusion, 84
microcin E492, 666
peptides
microcin 7, 791
porin channels, 84
resistance, 107
R plasmids
cloning from *S. aureus*, 79
urinary tract infections, 107
spheroplasts, 114
talisomycin, 460
tetracycline resistance
Tn10-mediated, 879
urinary tract infections, 107, 449
whole cells, 114
- [¹¹C]Ethanol
¹¹CO₂ production, 535
- Experimental infections
blastomycosis
amphotericin B, 363
Bay 1 9139, 363
Bay n 7133, 363
ICI 153066, 363
ketoconazole, 363
- C. albicans*
amphotericin B, 625
UK-49,858, 832
- colitis
temocillin, 980
- coxsackievirus
BIOLF-70, 184
- endocarditis
cefoperazone, 708
E. aerogenes, 708
enoxacin, 708
enterococci, 135
gentamicin, 224
pefloxacin, 685
S. aureus, 685
teicoplanin, 135
- herpes simplex virus
acyclovir, 167
- malaria
BA-41,799, 146
P. cynomolgi, 146
- meningitis
aztreonam, 655
BMV-28142, 340
cefotaxime, 340
cefpimizole, 340
E. coli K1, 655

- H. influenzae* type b, 655
 pneumococcal, 340
S. pneumoniae, 141
 pneumonia
 ciprofloxacin, 452
 P. aeruginosa, 452
 pefloxacin, 452
T. mentagrophytes
 UK-49,858, 832
 valvular lesions
 cefotaxime, 320
- Flavobacterium odoratum*
 β -lactamase, 612
- Fluoroquinolones
 WIN 49375
 antibacterial activity, 4
- Formycin B
 T. cruzi, 491
- Fusidic acid
 cardiac surgery, 928
 concentration in atrial appendages, 928
- Fusobacterium nucleatum*
 β -lactamase, 943
- Garlic
 Allium sativum
 mycobacterial inhibition, 485
- Genital pathogens
 quinoline derivatives, 76
- Genital tract infections
 female
 anaerobic bacterial susceptibility, 324
- Gentamicin
 Campylobacter spp., 429
 comparative activity, 429
 experimental infections
 endocarditis, 224
 nephrotoxicity, 812
 P. aeruginosa extracellular proteases,
 468
 pharmacokinetics, 285
 renal accumulation, 812
 renal disposition, 520
- Giardia lamblia*
 bithionol, 65
 dichlorophene, 65
 giardiasis, 227
 growth inhibition, 65
 hexachlorophene, 65
 tinidazole, 227
- Giardiasis
 G. lamblia, 227
 tinidazole, 227
- Gonorrhea
 aztreonam, 265
- Gram-negative bacteria
 polymyxin B nonapeptide, 541
- Gram-positive bacteria
 Sch 34343, 28
- Ground squirrel hepatitis virus
 arabinosyladenine monophosphate, 277
 9-(1,3-dihydroxy-2-propoxymethyl)guanine,
 277
- Guanine
 derivatives
 BIOLF-70, 184
- Haemophilus influenzae*
 amoxicillin-clavulanic acid, 912
- chloramphenicol, 46
 experimental infections
 aztreonam, 655
 meningitis, 655
 β -lactamase-positive, 912
 lower respiratory tract infections, 912
 resistance
 permeability barrier, 46
- HeLa cells
 C. trachomatis inhibition, 953
- Herpes simplex virus
 BCG vaccine, 203
 DNA polymerase
 aphidicolin, 445
 nucleoside analogs, 445
 phosphonoformate, 445
 experimental infections
 acyclovir, 167
 9-(1,3-dihydroxy-2-propoxymethyl)-
 guanine, 763
 latency, 763
 genital infections, 203
- Herpesvirus
 [2-¹¹C]-(2-deoxy-2-fluoro- β -D-arabinofur-
 anosyl)-5-iodocytosine
 biotransformation, 733
 elimination, 733
 9-(3,4-dihydroxybutyl)guanine, 753
 9-(4-hydroxybutyl)guanine, 753
- Hexachlorophene
 G. lamblia, 65
 T. vaginalis, 65
- High-pressure liquid chromatography
 amifloxacin, 769
 5-aminoimidazole-4-carboxamide, 977
 2-azahypoxanthine, 977
 ciprofloxacin, 353, 531
 comparative studies, 353
 dacarbazine, 977
 HR 810, 436
 vancomycin, 503
- HR 810
 anaerobic bacteria, 413
 comparative activity, 388
 enteropathogens, 388
 high-pressure liquid chromatography,
 436
 pharmacokinetics, 436
- Human prostate cells
 C. trachomatis inhibition, 953
- 9-(4-Hydroxybutyl)guanine
 antiherpesvirus effects, 753
 pharmacokinetics, 753
- ICI 153066
 comparative activity, 363
 experimental infections
 blastomycosis, 363
- Imipenem
 -cilastatin
 pharmacokinetics, 431, 511
 comparative activity, 1
 cystic fibrosis patients, 583
 endocarditis, 1
 high-dose treatment, 745
 P. aeruginosa, 1
 pharmacokinetics, 583
- Influenza virus
 ribavirin aerosol, 309
- Inosine
 analogs
 African trypanosomes, 33
- metabolism, 33
 tissue culture efficacy, 33
- Interferon
 aerosol, 60
 vesicular stomatitis virus, 60
- Isoniazid
 M. tuberculosis oxygen generation, 404
 oxidation
 mediation by peroxidase, 399
 superoxide-generating reactions, 408
- Isopenicillin N
 conversion from 8-(L-aminoadipyl)-L-
 cysteinyl-D-valine, 380
 P. chrysogenum, 380
- Ketoconazole
 comparative activity, 363
 experimental infections
 blastomycosis, 363
- Klebsiella pneumoniae*
 cephalosporins, 220
 iron-depleted, 220
 siderophore production, 220
 surface properties, 220
- β -Lactamases
 AER-1, 479
 A. faecalis, 608
 B. catarrhalis, 646
 E. cloacae resistance, 393, 455
 F. nucleatum, 943
 F. odoratum, 612
 induction test, 672
 β -lactam hydrolysis, 393
 OXA-2
 immunological comparison, 989
 OXA-4, 715
 OXA-5, 715
 OXA-6, 715
 OXA-7, 715
 TLE-1, 715
- β -Lactams
 anaerobic bacteria, 817
 comparative activity, 1, 817, 872
 disulfiram-like effects in rats, 535
 E. cloacae
 penetration, 555
 resistance, 393, 455
 E. coli porin channels, 84
 endocarditis, 1
 expanded-spectrum, 393
 hydrolysis, 393
 L. pneumophila, 695
 M. avium-intracellulare complex, 541
 P. aeruginosa, 1, 872
 N-sulfonated monocyclic
 carumonam, 821
 Y. enterocolitica, 806
- Lactoperoxidase
 B. cereus, 96
- Legionella micdadei*
 erythromycin-resistant, 272
- Legionella pneumophila*
 erythromycin-resistant, 272
 β -lactams, 695
- Leishmania* spp.
 sodium stibogluconate, 916
- Liposomes
 piperacillin activity, 137

- Macrolide antibiotics
 RU28965, 388
 Malaria
 antifol drugs, 525
 experimental
 BA-41, 799, 146
 P. cynomolgi, 146
 McCoy cells
 C. trachomatis inhibition, 953
 Membranes
 cytoplasmic
 nisin, 841
 whole cell
 nisin, 841
 Meningitis
 experimental
 aztreonam, 655
 BMV-28142, 340
 cefotaxime, 340
 cefepime, 340
 E. coli K1, 655
 H. influenzae type b, 655
 pneumococcal, 340
 S. pneumoniae, 141
 Metronidazole
 C. pasteurianum phosphoroclastic re-
 action, 863
 reduction, 863
 Microcin 7
 mode of action, 791
 structure, 791
 Microcin E492
 E. coli cytoplasmic membrane, 666
 Mirincamycin
 primaquine activity enhancement, 151
 Mitochondrial inhibitors
 P. falciparum, 21
 Monobactams
 half-lives, 887
 Moxalactam
 anaerobic bacteria, 424
 bleeding times, 858
 cephalosporinase binding, 727
 C. freundii, 727
 MICs, 424
 platelet responsiveness, 858
 pleural fluid
 clearance, 93
 penetration, 93
 prophylaxis
 cesarean section, 337
 susceptibility testing
 agar dilution, 424
 microdilution, 424
Mucor racemosus
 resistance, 892
 Mupirocin
 antibacterial activity, 495
 Mycobacteria
 inhibition
 garlic (*A. sativum*), 485
Mycobacterium aurum
 colistin, 701
Mycobacterium avium-intracellulare
 cefoperazone, 132
 cefotaxime, 132
 ceftizoxime, 132
 cephem susceptibility, 132
 complex
 β-lactams, 541
 morphological changes, 541
Mycobacterium chelonae
 susceptibility
 cefmetazole, 282
 Mycobacterium fortuitum
 susceptibility
 cefmetazole, 282
 Mycobacterium tuberculosis
 ceforanide, 11
 cephalosporins, 11
 isoniazid, 404
 oxygen generation, 404
 ribosome alteration, 921
 RNA polymerase, 921
 susceptibility
 radiometry, 11
 Myeloperoxidase
 B. cereus, 96
 Nalidixic acid
 Campylobacter spp., 429
 comparative activity, 429
Neisseria gonorrhoeae
 2-acetylpyridine thiosemicarbazones,
 570
Neisseria spp.
 R plasmid, 120
 Nephrotoxicity
 gentamicin, 812
 netilmicin, 812
 tobramycin, 812
 Netilmicin
 kinetic model, 343
 nephrotoxicity, 812
 renal accumulation, 812
 renal disposition, 520
 Nisin
 membranes
 cytoplasmic vesicles, 841
 whole cells, 841
 mode of action, 841
 structural similarities to Pep-5, 836
 Nonoxynol-9
 C. trachomatis, 720, 760
 Norfloxacin
 Aeromonas spp., 643
 comparative activity, 388, 419
 enteropathogens, 388
 P. shigelloides, 643
 urinary tract infections, 297, 419
 Nucleoside analogs
 Epstein-Barr virus, 416, 971
 herpesvirus DNA polymerase, 445
 Nucleoside antibiotics
 ascamycin, 230
 2'-O-Nucleotidyltransferase
 aminoglycosides
 enzymatic modification, 670
 resistance, 670
 Nystatin
 D. discoideum resistance, 974
 Ofloxacin
 comparative activity, 388
 enteropathogens, 388
 Oral microbes
 sanguinarine, 663
 Outer membrane proteins
 E. cloacae, 455
 Pediatric infections
 ceftriaxone, 181
 Pefloxacin
 experimental infections
 endocarditis, 685
 P. aeruginosa, 452
 pneumonia, 452
 S. aureus, 685
 Penems
 Sch 34343, 28, 128
 Penicillin
 C. difficile, 419
 L-cysteine, 419
 S. pneumoniae susceptibility
 experimental meningitis, 141
 streptococci
 reverse inoculum effect, 948
 Penicillin-binding proteins
 activity regulation, 828
 β-lactam-inducible, 851
 methicillin-inducible, 828
 S. aureus, 828
 staphylococci, 851
Penicillium chrysogenum
 isopenicillin N synthetase, 380
 Pentobarbital
 amikacin concentrations in body fluids,
 720
 Pep-5
 structural similarities to nisin, 836
 Peptide antibiotics
 nisin, 836, 841
 Pep-5, 836, 841
 Peroxidase
 isoniazid oxidation, 399
 Pharmacokinetics
 amifloxacin
 monkeys, 769
 aztreonam
 gram-negative infections, 16
 cefazolin
 effects of anesthesia, 874
 orthopedic surgery patients, 874
 ceforanide
 intraoperative, 487
 protein binding, 487
 cefotiam
 humans, 177
 ceftazidime
 cancer patients, 605
 cardiac vegetations, 925
 fibrin clots, 925
 ceftriaxone
 Chinese adults, 192
 cilastatin
 combined with imipenem, 511
 cystic fibrosis patients, 583
 neonates, 431, 511
 ciprofloxacin
 absorption, 350
 administration routes, 375
 effect of breakfast, 350
 multiple-dose, 350
 9-(3,4-dihydroxybutyl)guanine, 753
 gentamicin
 drug abusers, 285
 HR 810
 rabbits, 436
 9-(4-hydroxybutyl)guanine, 753
 imipenem
 combined with cilastatin, 511
 cystic fibrosis patients, 583
 neonates, 431, 511
 netilmicin
 two-compartment model, 343

- tobramycin
drug abusers, 285
vancomycin
continuous ambulatory peritoneal dialysis, 578
peritoneal drug transport, 578
Phosphonoacetate
structure-activity studies, 197
Phosphonoformate
herpesvirus DNA polymerase, 445
Picornavirus
WIN 51711, 883
Piperacillin
combined with ceftazidime
cancer patients, 605
liposome-mediated activity, 137
staphylococci, 137
Plasmids
R6K
elimination by bleomycin, 985
resistance
B. catarrhalis, 120
C. coli, 37
C. jejuni, 37
E. coli, 79, 107
Neisseria sp., 120
S. aureus, 79
staphylococci, 234
tetracycline
trimethoprim resistance
Tn7, 933
Plasmodium cynomolgi
experimental infections
BA-41, 799, 146
malaria, 146
Plasmodium falciparum
antimalarial activity
oxygen-dependent, 21
time-dependent, 21
chloroquine
resistance, 561
uptake, 561
erythrocytes, 561
mitochondrial inhibitors, 21
Platinum
biliary excretion, 275
cis-dichlorodiammineplatinum (II), 275
Plesiomonas shigelloides
ciprofloxacin, 643
enoxacin, 643
norfloxacin, 643
tetracycline, 643
trimethoprim-sulfamethoxazole, 643
Pneumococci
experimental infections
BMJ-28142, 340
cefotaxime, 340
cefepimazole, 340
meningitis, 340
Pneumonia
B. catarrhalis, 499
experimental
ciprofloxacin, 452
P. aeruginosa, 452
pefloxacin, 452
Polidocanol
S. aureus penicillin resistance, 632
Poliovirus
bismuth salts, 306
Polymorphonuclear leukocytes
aminoglycosides, 712
prostaglandin production, 257
Polymyxin B
nonapeptide
gram-negative bacteria, 541
Polymyxin E
see colistin
Pregnancy
bacteriuria, 508
Primaquine
activity enhancement
mirincamycin, 151
Probenecid
renal interaction, 660
urinary pH, 660
Prodrugs
alafosfalin, 961
Prostaglandins
clofazimine, 257
dapson, 257
polymorphonuclear leukocytes, 257
Pseudomonas aeruginosa
aztreonam, 1, 872
cefsulodin, 1
endocarditis, 1
experimental infections
ciprofloxacin, 452
pefloxacin, 452
pneumonia, 452
extracellular proteases, 468
gentamicin, 468
imipenem, 1
 β -lactams, 1, 872
peritoneal dialysis, 908
Ro 17-2301, 872
ticarcillin, 1
tobramycin
extracellular proteases, 468
resistance, 619
urinary catheters, 619
Pseudomonic acid
antibacterial activity, 495
Quinolines
derivatives
genital pathogens, 76
Quinolones
anaerobic bacteria, 657
comparative activity, 657
Radiometry
M. tuberculosis susceptibility, 11
Reovirus
bismuth salts, 306
Resistance factors
C. coli, 37
C. jejuni, 37
Respiratory tract infections
amoxicillin-clavulanic acid, 912
aztreonam, 246
B. catarrhalis, 912
clindamycin, 246
H. influenzae, 912
tobramycin, 246
Rhinovirus
4,6-dichloroflavin, 595
enviroxime, 102, 595
RMI-15,731, 595
Ro 09-0179, 595
Ro 09-0410, 595
44 081 R.P., 846
Ribavirin
aerosol
influenza virus, 309
Rift Valley fever virus, 903
Ribosomes
M. tuberculosis, 921
Rifampin
combinations, 615
staphylococci, 615
Rifapentine
combinations, 615
staphylococci, 615
Rift Valley fever virus
ribavirin, 903
RMI-15,731
comparative activity, 595
mechanism of action, 595
RNA polymerase
M. tuberculosis, 921
Ro 09-0179
comparative activity, 595
mechanism of action, 595
Ro 09-0410
comparative activity, 595
mechanism of action, 595
Ro 17-2301
comparative activity, 872
P. aeruginosa, 872
Rotavirus
bismuth salts, 306
44 081 R.P.
cell cultures, 846
RU28965
comparative activity, 388
enteropathogenesis, 388
Sanguinarine
comparative activity, 663
oral microbes, 663
Sch 34343
anaerobic bacteria, 749
comparative activity, 28, 128
enterococci, 28
gram-positive bacteria, 28
SF 86-327
fungal sterol biosynthesis, 252
mechanism of action, 252
Skin infections
ceftriaxone, 648
Sodium stibogluconate
biochemical mechanisms, 916
Soft tissue infections
ceftriaxone, 648
Spermicides
nonoxynol-9, 760
Staphylococci
coagulase-negative
R plasmids, 234
tetracycline, 234
methicillin-resistant
penicillin-binding protein, 851
piperacillin, 137
Staphylococcus aureus
experimental infections
endocarditis, 685
pefloxacin, 685
methicillin-resistant
ciprofloxacin, 688
penicillin-binding protein, 828
penicillin resistance
suppression, 632
polidocanol, 632
R plasmids
cloning into *E. coli*, 79
Staphylococcus saprophyticus

- amifloxacin, 449
urinary tract infections, 449
- Streptococci
group D
erythromycin resistance determinant, 439
Tn917-like sequences, 439
- penicillin
reverse inoculum effect, 948
- Streptococcus pneumoniae*
experimental infections
meningitis, 141
penicillin susceptibility, 141
- Streptomyces albobovineus*
treponemycin, 239
- Streptomycin
mutants
dihydrostreptose, 367
streptidine biosynthesis, 367
- Sulbactam
Campylobacter spp., 429
combined with ampicillin
anaerobic bacteria, 876
comparative activity, 429
- Sulfamethoxazole
trimethoprim-
Aeromonas spp., 643
Campylobacter spp., 429
comparative activity, 419, 429
enterococci, 71
P. shigelloides, 643
urinary tract infections, 158, 297, 419
V. cholerae resistance, 280
- Susceptibility testing
moxalactam
agar dilution, 424
microdilution, 424
MICs, 424
T. vaginalis
time-kill method, 332
- T-1982
see cefbuperazone
- Talisomycin
E. coli DNA breakage, 460
- Teicoplanin
experimental infections
endocarditis, 135
- Temocillin
bleeding times, 858
experimental infections
colitis, 980
platelet responsiveness, 858
- Tetracycline
Aeromonas spp., 643
P. shigelloides, 643
resistance
E. coli K-12, 879
Tn10-mediated, 879
staphylococcal resistance, 234
urinary tract infections, 652
- Tetrahydrofuran
derivatives
BA-41, 799, 146
- Ticarcillin
comparative activity, 1
efficacy, 291
endocarditis, 1
P. aeruginosa, 1
safety, 291
tobramycin nephrotoxicity, 897
- Tinidazole
giardiasis, 227
G. lamblia, 227
- Tioconazole
absorption, 964
persistence in vaginal fluid, 964
- Tissue culture cells
erythromycin
accumulation, 314
egress, 314
uptake, 314
- Tobramycin
combinations
cancer patients, 605
ceftazidime, 605
clindamycin, 246
respiratory tract infections, 246
nephrotoxicity, 812, 897
P. aeruginosa
extracellular proteases, 468
urinary catheters, 619
pharmacokinetics, 285
renal accumulation, 812
renal disposition, 520
renal function
shock, 217
- Topical antibiotics
mupirocin (pseudomonic acid), 495
- Treponema hyodysenteriae*
treponemycin, 239
- Treponemycin
T. hyodysenteriae, 239
- Trichomonas vaginalis*
bithionol, 65
dichlorophene, 65
growth inhibition, 65
hexachlorophene, 65
susceptibility testing
time-kill method, 332
- Trichophyton mentagrophytes*
experimental infections
UK-49,858, 832
- Trimethoprim
enterococci, 71
resistance
chromosomally mediated, 933
plasmid-borne, 933
Tn7, 933
-sulfamethoxazole
Aeromonas spp., 643
Campylobacter spp., 429
comparative activity, 419, 429
enterococci, 71
P. shigelloides, 643
urinary tract infections, 158, 297, 419
V. cholerae resistance, 280
- Trypanosoma cruzi*
formycin B, 491
- U63196-E
see cefpimizole
- UK-49,858
experimental infections
C. albicans, 832
T. mentagrophytes, 832
- Urinary catheters
P. aeruginosa, 619
- Urinary tract infections
amifloxacin, 449
ceftriaxone, 158
E. coli, 107, 449
norfloxacin, 297, 419
S. saprophyticus, 449
tetracycline hydrochloride therapy, 652
trimethoprim-sulfamethoxazole, 158, 297, 419
- Valvular lesions
experimental
cefotaxime, 320
- Vancomycin
high-pressure liquid chromatography, 503
pharmacokinetics
continuous ambulatory peritoneal dialysis, 578
peritoneal drug transport, 578
- Ventricular fibrillation
amphotericin B infusion, 868
- Vesicular stomatitis virus
interferon aerosol, 60
- Vibrio cholerae*
resistance
plasmid-mediated, 280
trimethoprim-sulfamethoxazole, 280
- Vidarabine
combined with acyclovir, 600
cytomegalovirus, 600
- WIN 39375
see amifloxacin
- WIN 51711
in vitro activity, 883
picornavirus, 883
- Yersinia enterocolitica*
 β -lactams, 806
- Yersinia ruckeri*
plasmid-mediated resistance, 938
susceptibility patterns, 938
- YM-13115
in vitro activity, 565
- Zinc
C. trachomatis inhibition, 953

